{"prompt": "['MEIRAGTx', 'Gene Therapy for Achromatopsia (CNGA3)', '1.2', 'Sponsor', 'MeiraGTx UK Il Ltd., 92 Britannia Walk, London N1 7NQ, is the study sponsor.', 'CNGA3 MGT012 Protocol version 6.0 16Apr2021', 'Page 8 of 68']['MEIRAGTx', 'Gene Therapy for Achromatopsia (CNGA3)', '1.3', 'Structured trial summary', 'Primary', 'Registry', 'and', 'Trial', 'EudraCT 2018-003431-29', 'Identifying Number', 'Secondary Identifying Numbers', 'MeiraGTx UK II Ltd. registration number: MGT012', 'Source of Monetary or Material', 'MeiraGTx UK II Ltd.', 'Support', 'Sponsor', 'MeiraGTx UK II Ltd.', 'Contact for Public Queries', 'ocularinfo@meiragtx.com', 'Contact for Scientific Queries', 'Chief Medical Officer (MeiraGTx)', '450 East 29th Street', '14th Floor', 'New York, NY 10016', 'Tel : 646-869-7379', 'Email :', 'Public Title', 'Gene Therapy for Achromatopsia (CNGA3)', 'Scientific Title', 'An open label, multi-centre, Phase I/II dose escalation trial of', 'an adeno-associated virus vector (AAV8-hG1.7p.coCNGA3)', 'for gene therapy of children with Achromatopsia owing to', 'defects in CNGA3', 'Countries of Recruitment', 'United Kingdom, United States of America', 'Health Condition', 'Achromatopsia', 'Intervention(s)', 'Open label, non-randomised, dose-escalation', 'Phase I/II dose-escalation study, by subretinal administration', 'of AAV8-hG1.7p.coCNGA3 in up to 18 paediatric participants', 'with Achromatopsia owing to mutations in the CNGA3 gene.', 'Key Inclusion and Exclusion Criteria', 'Key Inclusion Criteria:', 'Aged 3 to 15 years old', 'Achromatopsia caused by mutations in CNGA3', 'Evidence of relative preservation of photoreceptors at', 'the macula', 'Able to undertake age-appropriate clinical assessments', 'Willing to give consent for the use of blood and blood', 'components collected throughout the trial for the', 'investigation of immune response to Advanced Therapy', 'Investigational Product (ATIMP).', 'Key Exclusion Criteria:', 'Female adolescents who are pregnant or breastfeeding', 'Intra-ocular surgery within 9 months of screening', 'Ocular or systemic disorder that may preclude subretinal', 'surgery and/or interfere with interpretation of the study', 'results.', 'CNGA3 MGT012 Protocol version 6.0 16Apr2021', 'Page 9 of 68']['MEIRAGTx', 'Gene Therapy for Achromatopsia (CNGA3)', 'Participated in another research study involving an', 'investigational therapy for ocular disease within the last', '6 months', 'Use of high dose regular non-steroidal anti-inflammatory', 'drugs at the time of screening', 'Have any other condition that the Principal Investigator', '(PI) considers makes them inappropriate for entry into', 'the trial', 'Are unwilling to consider the possibility of entry into a', 'subsequent longer term follow up study', 'During the 6 weeks prior to baseline, have had any', 'confirmed SARS-CoV-2 (COVID-19) infection', 'Study Type', 'Phase I/II, open-label, non-randomised, multi-centre, dose', 'escalation study, followed by dose confirmation in children', 'with Achromatopsia owing to defects in CNGA3', 'Date of First Enrolment', 'Anticipated Q1 2019', 'Target Sample Size', 'Up to 18 participants', 'Primary Outcome(s)', 'The primary outcome is safety of subretinal administration of', 'AAV8-hG1.7p.coCNGA3.', 'Safety is defined as the absence of ATIMP-related:', 'Reduction in visual acuity by 15 ETDRS letters or', 'more that fails to resolve to within 15 letters of', 'baseline in a 4-week period once prophylactic', 'treatment commences', 'Severe unresponsive inflammation', 'Infective endophthalmitis', 'Ocular malignancy', 'Grade III or above non-ocular SUSAR', 'Safety will be assessed for 6 months after the intervention in', 'this study, and a further optional 4.5 years in a separate', 'subsequent study.', 'Key Secondary Outcomes', 'The secondary outcomes are measures of the efficacy of the', 'intervention, which will be performed on an individual', 'participant basis and will be descriptive in nature. Efficacy will', 'be assessed at several time points between 3 to 6 months', 'after the intervention:', '1) Any improvement in visual function from baseline that is', 'greater than the baseline variation for that test and is', 'sustained for at least two consecutive assessments.', '2) Any improvement in retinal function from pre-intervention', 'that is greater than the baseline variation and measurable by', 'electroretinography (ERG).', '3) Quality of life measures including EQ-5D and IVI or', 'equivalent as appropriate.', 'CNGA3 MGT012 Protocol version 6.0 16Apr2021', 'Page 10 of 68']\n\n###\n\n", "completion": "END"}